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Abstract 
Objective: The pathogenetic mechanisms by which HLA-DRB1 alleles are associated with 
ACPA-positive rheumatoid arthritis (RA) are incompletely understood. RA high-risk HLA-
DRB1 alleles are known to share a common motif, the “shared susceptibility epitope (SE)”. 
Here, the electro-positive P4-pocket of HLA-DRB1 accommodates self-peptide residues 
containing citrulline but not arginine. HLA-DRB1 His/Phe13stratifies with ACPA-positive 
RA, while His13Ser polymorphisms stratify with ACPA-negative RA and RA-protection. 
Indigenous North American (INA) populations have high risk of early-onset ACPA-positive 
RA, whereby HLA-DRB1*04:04 and 14:02 are implicated as risk factors for RA in INA. 
However HLA-DRB1*14:02 has a His13Ser polymorphism. Therefore, we aimed to verify 
this association and determine its molecular mechanism.  
Methods: HLA genotype was compared in 344 INA RA patients and 352 controls.  Structures 
of HLA-DRB1*1402-class II loaded with vimentin-64Arg59-71, vimentin-64Cit59-71 and 
fibrinogen-74Cit69-81 were solved using X-ray crystallography. Vimentin-64Cit59-71 and 
vimentin59-71-specific CD4+ T cells were characterised by flow cytometry using pHLA 
tetramers. After sorting of antigen-specific T cells, TCRα and β chains were analyzed using 
multiplex, nested PCR and sequencing.   
Results: ACPA+ RA in INA was independently associated with HLA-DRB1*14:02. 
Consequent to the His13Ser polymorphism and altered P4-pocket of HLA-DRB1*14:02, 
both citrulline and arginine were accommodated in opposite orientations. Oligoclonal 
autoreactive CD4+ effector T-cells reactive with both citrulline and arginine forms of 
vimentin59-71 were observed in HLA-DRB1*14:02+ RA patients and at-risk ACPA- first-
degree relatives. HLA-DRB1*14:02-vimentin59-71-specific and HLA-DRB1*14:02-vimentin-
64Cit59-71-specific CD4+ memory T cells were phenotypically distinct populations. 
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Conclusion: HLA-DRB1*14:02 broadens the capacity for citrullinated and native self-peptide 
presentation and T cell expansion, increasing risk of ACPA+ RA. 
 
INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease with peak incidence in the sixth decade 
and prevalence of 1% in Caucasians, linked to HLA-DRB1. HLA-DRB1 alleles associated with 
anti-citrullinated peptide antibody (ACPA)-positive RA in Caucasians share a common motif 
in the third hypervariable region, the “shared susceptibility epitope (SE)” that was shown to 
accommodate citrullinated self-epitopes [1-3]. Citrulline is post-translationally modified from 
arginine during inflammation, ER stress and autophagy [4, 5]. Various RA-associated 
citrullinated (Cit) autoantigens, recognised by ACPA, are present in inflamed lung and joint 
tissues. Low titre ACPA develop in healthy individuals associated with environmental risk 
factors including smoking, bronchiectasis and periodontitis, but are unrelated to HLA-DR SE 
[6-11]. In the immediate pre-RA period, ACPA isotype diversity and titre increase – a process 
associated with antigen-specific CD4+ T cell help for affinity maturation in germinal centres 
[8]. HLA-DR SE are associated with ACPA+ RA rather than ACPA, implying that presentation 
of Cit-autoantigens bound to HLA-DR SE molecules to CD4+ T cells is associated with RA 
development in at-risk individuals carrying HLA-DR SE.  
 
Based on genome-wide studies (GWAS) in patients of predominantly Caucasian and Asian 
ethnicity, HLA alleles associated with ACPA-positive RA, including HLA-DRB1*04:01, 
*04:05 and *01:01 (odds ratios of 2.17-4.44) were found to share a common motif at amino 
acid positions 11, 13, 71 and 74, influencing the P4 antigen-binding pocket of DR [2]. 
Moreover, Val11Ser and His13Ser polymorphisms within that motif were found in genomic 
studies to stratify with ACPA-negative RA in Caucasians [3]. The discovery that P4-Cit was 
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accommodated, but the positively-charged Arg was excluded from the electro-positive P4-
pocket of HLA-DRB1*04:01/04 suggested that preferential presentation of Cit-autoantigens 
might underpin the association of ACPA+ RA with the SE [12]. While HLA-DRB1*04:01-
restricted CD4+ memory T cells recognizing Cit-autoantigens have been reported in RA 
patients [12, 13], their role in disease development is unclear. To date it has not been 
determined how autoreactive T cells respond to citrullinated autoantigen in RA and whether 
they undergo clonal expansion due to antigen experience in RA patients or in HLA-SE+ at-
risk first-degree relatives (FDR).  
 
Furthermore, in unravelling antigen presentation by HLA-DR molecules in RA, the ethnic mix 
of the samples included in GWAS may skew interpretations of amino acids contributing to 
binding motifs made from genomic studies. The Indigenous North American (INA) population 
has a 2-3 fold higher prevalence of RA than Caucasians, with RA onset peaking earlier, in the 
fourth decade of life [14]. Moreover, 90% of INA RA patients are ACPA+. In this population, 
FDR have a high prevalence of joint symptoms and of ACPA positivity, predisposing them to 
RA [15, 16]. To date, the HLA association with RA in INA has been sought in studies of <100 
patients [17-19]. These studies suggested that the HLA-SE-alleles also predispose to RA in 
INA. HLA-DRB1*04:04 is the most frequent SE-allele in these populations followed by HLA-
DRB1*14:02. Since HLA-DRB1*14:02 carries the 13Ser residue, which was interpreted to 
stratify with ACPA-negative RA [3], we investigated the genetic and underlying molecular 
bases for the increased risk of severe ACPA+ RA in INA.    
 
MATERIALS AND METHODS 
Study participants  
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RA cases, non-RA controls and first-degree relatives (FDR) were recruited from INA 
populations in Central Canada (Cree, Ojibway, and Ojicree) and Alaska Native people (from 
Southcentral and Southeast Alaska). DNA for HLA typing, serum and PBMC were isolated.  
   
HLA-DRB1*14:02 expression and purification 
Peptide-loaded HLA-DRB1*14:02 molecules were purified, crystallised and structures 
determined.  
 
Multiplex ACPA assay  
Serum levels of antibodies targeting 40 putative RA-associated autoantigens were measured 
using a custom bead-based immunoassay on a Bio-Plex platform, as previously described [20]. 
 
Tetramer staining and analysis of TCR repertoire 
Tetramer staining and TCR repertoire analysis used previously published methods, with some 
modifications [12, 21, 22]. 
Details of all methods available in Supplementary methods, Supplementary Table 1 and 
Supplementary Figure 1.  
 
RESULTS 
HLA-DRB1*14:02 is independently associated with ACPA+ RA in INA 
Although very rare in Caucasians and Asians, HLA-DRB1*14:02 has a prevalence of up to 
80% in some INA populations, suggesting a particular survival advantage against pathogens 
[17-19]. To determine the HLA-DRB1 association with ACPA+ RA in INA, we genotyped the 
largest cohort available, comprising 344 INA RA patients and 352 controls. Rheumatoid factor 
(RF) and ACPA status was known in 241/344 RA patients: 90% were seropositive (RF and/or 
ACPA+). In seropositive RA patients, 32% carried HLA-DRB1*14:02 and 45% HLA-
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DRB1*04:04. One third of patients carrying HLA-DRB1*14:02 carried an additional SE allele. 
In healthy controls, 28% carried DRB1*14:02, 22% HLA-DRB1*04:04 and 17% carried an 
additional SE allele. After stratifying RA patients according to HLA-status, HLA-DRB1*14:02 
was a risk factor for seropositive RA (OR 2.38) independent of other SE alleles (Table 1). In 
INA RA patients, the most commonly associated other SE allele is HLA-DRB1*04:04 (Table 
1). In INA, RA risk was associated with HLA-DRB1 alleles with a conserved SE motif at 71 
and 74 in all RA (OR = 2.48, 95% CI = 1.70-3.60, P<0.0001) and in seropositive RA (OR = 
2.46, 95% CI = 1.58-3.81, P=0.0001) patients (Table 1). We note that without genome-wide 
genotyping, we cannot rule out the possibility of confounding due to case-control differences 
in ancestry.  
 
To stratify ACPA response with genotype, sera of 232 INA RA patients were tested in a 
multiplex ACPA antigen array and given an ACPA score (sum of all normalized ACPA titers 
divided by number of epitopes) [23]. ACPA score was higher in INA RA patients who were 
either HLA-DRB1*14:02 homozygotes or HLA-DRB1*14:02/HLA-SE compound 
heterozygotes than those who were HLA-SE-negative (p<0.05). ACPA scores in HLA-
DRB1*14:02+ patients were equivalent to those in HLA-SE+ patients lacking HLA-
DRB1*14:02. ACPA specificities increased among HLA-DRB1*14:02+ patients included 
vimentin-64Cit58-77, filaggrin-56Cit48-65 and fibrinogen--573Cit556-575 (Figure 1a, 1b). Thus, 
despite polymorphisms of Val11Ser and His13Ser, INA individuals carrying HLA-
DRB1*14:02 develop a broad ACPA-response whether or not they carry other SE alleles. This 
implies binding and presentation of a variety of Cit-autoantigens by HLA-DRB1*14:02 to 
autoreactive T cells.  
 
Accommodation of arginine and citrulline residues within the P4 pocket of HLA-
DRB1*14:02. 
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The HLA-DRB1 chain contains 12 polymorphic residues that have been directly implicated in 
peptide binding [24]. HLA-DRB1*14:02 differs from *04:01, *04:04 or *01:01 in 8 of these  
residues, which shape P4, P6, P7 and P9 pockets (Figure 2a).  To test whether HLA-
DRB1*14:02 presents autoantigens differently to  HLA-DRB1*04:01, *04:04 or *01:01, we 
compared the capacity of each HLA binding pocket to accommodate Cit and Arg residues 
using the influenza-derived HA305-319 peptide [25-28]. Conversion of Arg to Cit at peptide-
positions interacting with P4 enhanced peptide binding affinity to HLA-DRB1*01:01 by 2 
fold and to *04:01 by 10 fold. Conversion of Arg to Cit at peptide-positions interacting with 
the P6 and P9 pockets enhanced peptide binding affinity to HLA-DRB1*01:01, and P7 to 
HLA-DRB1*04:01. In contrast, peptides containing an Arg or Cit residue at positions 
interacting with P4 of HLA-DRB1*14:02 had similar binding affinity, and peptides containing 
Arg at positions interacting with P6 and P9 had increased affinity relative to Cit-peptides 
(Figure 2b). While the IC50 of the self-peptide, vimentin64Cit59-71, was decreased by 1.3 fold 
relative to the 64-Arg variant for HLA-DRB1*01:01, and the 64-Arg variant did not bind 
*04:01, HLA-DRB1*14:02 bound both 64-Arg and 64-Cit variants with IC50 of 19 M 
(Figure 2c), indicating that both residues could be accommodated within P4 of HLA-
DRB1*14:02, or that HLA-DRB1*14:02 presented in differing peptide binding registers. 
 
Structural basis of peptide presentation by HLA-DRB1*14:02 
We solved the structure of HLA-DRB1*14:02 in complex with vimentin64Arg59-71, 
vimentin64Cit59-71 and fibrinogen74Cit69-81 (Supplementary Table 2, Figures 3a-d).  These 
HLA-DRB1*14:02 structures overlaid closely (Figure 3e), ruling out markedly differing 
binding modes to accommodate these differing epitopes.  Within the HLA-DRB1*14:02-
vimentin64Cit59-71 and HLA-DRB1*14:02-vimentin64Arg59-71 structures, Tyr, Ser and Arg 
occupied the P1, P6 and P9 pockets of HLA-DRB1*14:02, respectively (Figure 3b,c). In the 
HLA-DRB1*14:02- fibrinogen 74Cit69-81 complex, Tyr, Ala and Ala occupied the P1, P6 and 
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P9 pockets of HLA-DRB1*14:02, respectively (Figure 3d). The largest structural differences 
between the peptides in each binary complex centered on the residue occupying the P4-pocket 
of HLA-DRB1*14:02, namely P4-Cit and P4-Arg in vimentin64Cit59-71, fibrinogen 74Cit69-
81 and vimentin64Arg59-71, respectively. These structures clearly show that P4-Arg and P4-Cit 
are presented in alternative orientations, whereby the P4-Arg projects inwards, whereas the 
P4-Cit projects outwards from the HLA-DRB1*14:02 Ag-binding cleft (Figures 3f-h). The 
P4-Arg is buried in the pocket to avoid interactions with the positively charged β71Arg 
residue. This orientation is promoted by β11Ser and β13Ser, whereupon these two small polar 
residues allow the accommodation of Arg by providing the necessary space and H-bonding 
partners (Figure 3f). Larger residues in HLA-DRB1*04:01 (β11Val and β13His) and HLA-
DRB1*01:01 (β11Leu and β13Phe) as well as the charge repulsion of β13His in HLA-
DRB1*04:01 would prevent the accommodation of Arg at P4 [12]. The P4-Arg residue is 
stabilized by H-bonds with Ser11, Ser13 and Tyr30, and a salt bridge with Glu28 (Figure 
3f). In contrast, the P4-Cit sits upright in both Cit-epitopes, similar to its orientation in P4-Cit 
from Cit epitopes presented by HLA-DRB1*04:01/04:04 (Figures 3g,h) [12]. The P4-Cit is 
stabilized by H-bonds with Arg71β and Gln70 (Figure 3g,h). Accordingly, we demonstrate 
a conserved positioning of the citrulline residue in two distinct epitopes that contrast the 
orientation of the non-citrullinated residue within the P4-pocket. Similar to its orientation in 
HLA-DRB1*04:01 and HLA-DRB1*04:04 [12, 29], P4-Cit was solvent-exposed in HLA-
DRB1*14:02, and could potentially interact with TCR. 
 
Antigen-experienced, oligoclonally-expanded T cells recognize Arg and Cit-variants of 
vimentin59-71 presented by HLA-DRB1*14:02 
Although both vimentin 64-Arg and 64-Cit variant peptides bound HLA-DRB1*14:02, only 
P4-Cit sits upright, and thereby potentially able to interact with the TCR. Thus, we addressed 
whether autoreactive T cells with TCRs recognizing one or both epitopes were present in the 
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periphery and displayed evidence of in vivo expansion in response to antigen presentation. We 
analysed T cells recognizing HLA-DRB1*14:02-vimentin64Cit59-71 and HLA-DRB1*1402-
vimentin59-71 tetramers in ten HLA-DRB1*14:02+ INA RA patients, ten HLA-DRB1*14:02+ 
ACPA- FDR, and 6 HLA-DRB1*14:02+ non-INA healthy control (HC) subjects. FDR in the 
INA population have a high burden of environmental risk factors for RA, a high level of 
background HLA-DR SE genes, high inflammatory CRP and a high prevalence of joint 
symptoms [16]. Among the 13 FDR studied (Supplementary Table 3) 85% were past 
smokers and 31% had an abnormal CRP >8. Therefore we could compare T cells recognizing 
vimentin or Cit-vimentin in individuals both with RA and with high risk of future RA. Similar 
frequencies of CD4+ T cells recognized vimentin 64-Arg and 64-Cit variant peptides in HLA-
DRB1*14:02+ FDR and RA patients, and with similar tetramer staining intensity (MFI) 
(Figure 4a, b). In all individuals, HLA-DRB1*14:02-vimentin64Cit59-71-reactive and HLA-
DRB1*14:02-vimentin59-71-reactive CD4+ T cells were significantly enriched in 
CD25+CD127+ effector (Teff) and CD25+CD127- regulatory T cells (Treg) [30] compared to 
the total CD4+ PB T cell pool (Treg p<0.0001, Teff p<0.05, Figure 4c), consistent with antigen 
experience in vivo. This enrichment did not differ between RA patients and FDR, indicating 
that antigen experience and formation of memory develops before the onset of ACPA in INA. 
The numbers of circulating HLA-DRB1*14:02-vimentin64Cit59-71-reactive and HLA-
DRB1*14:02-vimentin59-71-reactive CD4+ T cells were correlated in each individual RA 
patient and FDR (r2=0.74, p<0.0001, Figure 4d).  
 
T cell effector function is balanced by the suppressive activity of Treg [31]. The ratio of HLA-
DRB1*14:02-vimentin59-71Cit64-reactive and HLA-DRB1*14:02-vimentin59-71-reactive Teff/ 
Treg was significantly lower than that of the total CD4+ T cell pool in RA patients and FDR 
(p<0.001, Figure 4e), consistent with active regulation of the autoreactive T cells. To 
understand the particular role of CD4+ T cells of each vimentin specificity further, we analysed 
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an additional 6 HLA-DRB1*14:02+ INA individuals (3 with RA, 3 FDR, clinical details in 
Supplementary Table 3) and 6 HLA-DRB1*14:02+ HC for markers of memory T cell 
activation and differentiation relative to total CD4+ T cells. In INA RA patients and FDR the 
proportion of CD28+ memory T cells was significantly higher among vimentin59-71-reactive 
CD4+ T cells (p<0.05, Figure 4f). Moreover, cells expressing CD69 were significantly 
enriched among vimentin59-71-reactive CD4+ T cells in these individuals. Some CD69+ 
vimentin59-71-reactive memory CD4+ T cells also expressed NKG2D (Figure 4g). In contrast, 
HC Vimentin64Cit59-71-reactive and vimentin59-71-reactive CD4+ T cells did not differ in 
phenotype from total CD4+ T cells and the numbers of vimentin64Cit59-71-reactive and 
vimentin59-71-reactive CD4+ T cells did not correlate (Supplementary Figure 2). Thus, in INA 
FDR and RA patients but not HC, T cells reflect antigen-driven activation and differentiation.  
 
TCR bias and oligoclonal TCR reactive with vimentin64Cit59-71 and vimentin59-71 
To obtain evidence of in vivo expansion in HLA-DRB1*14:02+ INA, we used multiplex PCR 
to sequence the TCRs from a total of 53 single vimentin59-71-reactive and 71 vimentin-64Cit59-
71-reactive tetramer-positive CD4+ T cells derived from five HLA-DRB1*14:02+ RA patients 
and five HLA-DRB1*14:02+ FDR. TRAV and TRBV gene usage among CD4+ T cells reactive 
to each vimentin epitope was generally diverse in RA and FDR (Supplementary Table 4). 
However, TRBV20-1 and TRBV30 were preferentially used variable gene segments for 
recognition of vimentin 64-Arg and 64-Cit variant peptides bound to HLA-DRB1*14:02 
(Figure 4h). TRAV13-2 and TRAV26-1 were preferentially used variable gene segments 
among both vimentin59-71- reactive and vimentin-64Cit59-71- reactive TCRs. Use of preferential 
variable gene segments in the repertoires of T cells recognizing each epitope was observed in 
both RA patients and FDR and suggested underlying oligoclonality of the autoreactive T cell 
populations when compared with the total CD3+ T cell population (Figure 4h). Indeed, 
multiple vimentin64Cit59-71- reactive and vimentin59-71- reactive CD4+ T cells bearing the same 
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CDR3 and/or CDR3 sequences were identified amongst the single cells sorted from 2 of 
the RA patients and 2 FDR (Table 2). In two FDR, CD4+ T cells bearing the same TRBV30 
CDR3 sequences were identified multiple times among single cells reactive for vimentin 64-
Arg and 64-Cit variant peptides bound to HLA-DRB1*14:02. In one RA patient, the same 
TRBV2 CDR3 sequences were identified multiple times among single vimentin-64Cit59-71-
reactive CD4+ T cells, and in another patient, the same TRBV10-3 CDR3 sequences were 
identified multiple times among single vimentin59-71-reactive CD4+ T cells. These repeated 
CDR3 and CDR3 sequences indicate antigen-reactive clonal expansion within the blood of 
these HLA-DRB1*14:02+ patients and at-risk FDR (Table 2). In all cases, clonally expanded 
tetramer+ T cells were CD4+CD25+CD127+ Teff, as determined by index sorting. Individuals 
in whom any oligoclonal sequences were detected in PB were more likely to be HLA-
DRB1*14:02 homozygous or HLA-DRB1*14:02/*04:04 compound heterozygous than 
individuals without oligoclonal expansion (p<0.05, Chi2 test). Remarkably, a common 
TRBV30 CDR3 sequence (SI/VGAGNQPQ) was expanded in the blood of 2 individual FDR, 
which in each case encoded TCRs recognizing vimentin59-71 as well as vimentin-64Cit59-71. Of 
34 sorted antigen-reactive T cells yielding productive TRBV gene sequences from FDR, 
23.5% contained this CDR3 sequence. We used retroviral vectors encoding HLA-DR14:02-
vimentin59-71-restricted TCR P2F3 (Supplementary Table 4, bold) to transduce the αβ TCR-
deficient SKW-3 cell line [32, 33]. When stimulated with HLA-DRB1*14:02-vimentin59-71 or 
vimentin-64Cit59-71 tetramers, P2F3 SKW-3 cells upregulated pERK relative to HLA-
DRB1*14:02-CLIP tetramers (Figure 4i), confirming that TCR identified from cells with 
HLA-DRB1*14:02-vimentin59-71 tetramer reactivity recognize vimentin59-71 and vimentin-
64Cit59-71 in the context of HLA-DRB1*14:02.  
 
The biased TCR usage suggests a structural requirement for conserved amino acid sequences 
to recognise vimentin59-71 and vimentin-64Cit59-71. Nucleotide sequences encoding TRBV30 
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CDR3reveal that although the second N region at the D-J junction in each TCR is different, 
they encode the same amino acid sequence (Table 2). These data implicate convergent 
recombination events in the selection of this sequence during TCR gene rearrangement [34].  
 
DISCUSSION 
 
HLA-DRB1*14:02 and HLA-DRB1*04:04 are shown to be independent risk alleles for ACPA+ 
RA in the INA population. Analysis of the structures and T cell responses to citrullinated and 
non-citrullinated epitopes shows that, consequent to the His13Ser polymorphism and altered 
P4-pocket, HLA-DRB1*14:02 can present both variant peptides. This contrasts with structures 
of HLA-DRB1*04:01 and *04:04, in which Cit but not Arg can be accommodated in P4 [12, 
29]. Presentation of both 64-Cit and 64-Arg vimentin59-71 variants promoted autoreactive CD4+ 
T cell activation and differentiation to Teff and Treg, and clonal expansion of Teff in HLA-
DRB1*14:02+ RA patients and at-risk FDR. In HLA-DRB1*14:02+ HC, we observed no 
activation or differentiation of antigen-specific T cells above the background total CD4+ T 
cells. Previous studies of CD4+ T cells in individuals carrying Caucasian SE alleles show that 
T cell responses to Cit-autoantigenic peptides are increased relative to Arg-variant peptides 
[12, 29, 35, 36], reinforcing that T cell function aligns with HLA-DR-peptide structure.  
 
We show preferential variable gene segments and clonally-expanded TCR among vimentin59-
71- and vimentin-64Cit59-71–reactive CD4+CD25+CD127+ Teff sorted from RA patients and 
FDR, including a public TRBV CDR3. These data suggest that presentation of vimentin self-
epitopes in vivo continues in genetically predisposed individuals before and after onset of RA, 
and selects T cells making productive TCR rearrangements, as identified by the nucleotide 
sequences, for antigen recognition and T cell expansion.  
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Although limited by small sample numbers, the phenotypic profiles of 64-Cit and 64-Arg 
variant-specific autoreactive T cells appeared to be different. The fibroblast antigen, vimentin, 
has widespread tissue expression [37]. Vimentin 64-Arg-specific memory CD4+ T cells 
specifically expressed CD69. CD69 is a marker of recent activation or tissue residency and 
exposure to cytokines such as TNF [30], suggesting that vimentin59-71-reactive T cells are 
activated in tissue inflammatory sites. NKG2D signifies Teff costimulatory function and is 
TNF-activated [31]. Intriguingly, our data suggest cross-reactivity of some TCRs for the 64-
Cit and 64-Arg variants: cell frequency of each specificity was correlated, the public clonotype 
occurred in T cells reactive with each variant, and T cells expressing TCR P2F3 were activated 
with both tetramers. In general, co-expansion of T cells recognising Cit and Arg variants might 
be advantageous, e.g. for cross-protection against infectious antigens requiring rapid immunity 
[38-40]. This suggests a hypothesis for persistence of HLA-DRB1*14:02 in the INA 
population, even though its molecular structure permits presentation of multiple self-antigens 
driving ACPA+ RA. 
 
Low titre ACPA develop in healthy individuals independent of HLA-DR SE, particularly in 
inflammatory contexts [6-8, 10, 11]. In HLA-DR SE+ individuals, memory T cells driven by 
antigen experience would provide required B cell help for increased titres and epitope 
spreading in patients developing RA [8, 41, 42]. Since HLA-DRB1*14:02 broadens capacity 
for autoantigen presentation and T cell expansion, our study provides a mechanism for 
enhanced risk of early onset of ACPA+ RA in INA.   
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Figures 
 
Figure 1. HLA-DRB1*14:02 is associated with a broad ACPA response  
Serum levels of antibodies targeting RA-associated Cit-autoantigens were measured in serum 
from 232 INA RA patients using a custom bead-based fluorescence immunoassay. 
Fluorescence intensities for 10 Cit-autoantigens and CCP were clustered (a) according to the 
presence or absence of 1 or 2 HLA-DR-SE alleles or HLA-DRB1*14:02 with any HLA-DR-
SE allele, and (b) according to presence or absence of a single HLA-DR-SE or HLA-
DRB1*14:02 allele, as shown. Each column represents one patient sample.  
 
Figure 2. Accommodation of arginine and citrulline residues by HLA-DRB1*01:01, 
DRB1*04:01 and DRB1*14:02. (a) The peptide binding groove of a HLA-DR molecule is 
shown in cartoon with polymorphic residues shown as sticks corresponding to the residues 
present in HLA-DRB1*14:02, which is associated with RA among the INA. Schematic 
representation of the differences in pockets between HLA-DRB1*14:02 (red font), *04:01 
(black font) and *01:01 (blue font). (b) Competitive binding of a biotin-labelled HA305-319 
peptide with an unlabelled HA305-319 peptide or HA305-319-variants with citrulline or arginine 
residues in P1, P4, P6, P7 and P9 to HLA-DRB1*01:01 , DRB1*04:01  and DRB1*14:02. ND 
= Non-detectable binding affinity. Pooled binding data from at least 3 experiments are shown 
and error bars depict the variation between experiments. (c) Competitive binding of a biotin-
labeled HA305-319 peptide with unlabeled vimentin59-71 and vimetin-64Cit59-71 to HLA-
DRB1*01:01, *04:01 and *14:02.  
 
 
Figure 3. Crystal structure of HLA-DRB1*1402 in complex with vimentin59-71, vimentin-
64Cit59-71 and fibrinogenβ 74Cit69-81   
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The α- and β-chains of (a) the HLA-DRB1*1402 in complex with vimentin59-71 are shown in 
cartoon representation and coloured in light green and light blue respectively, while peptide is 
displayed as sticks. Side view of (b) HLA-DRB1*1402-vimentin59-71, (c) HLA-DRB1*1402-
vimentin-64Cit59-71 and (d) HLA-DRB1*1402-fibrinogenβ74Cit69-81. The carbons are 
coloured deep salmon, light orange and teal for vimentin59-71, vimentin-64Cit59-71 and 
fibrinogenβ 74Cit69-81, respectively, nitrogens are coloured in blue and oxygens are coloured 
in red. The β-chain is transparent to help visualize the peptide. The unbiased 2Fo-Fc electron 
density map of the peptides is shown in blue and contoured to 1 σ. (e) Superposition of the 
three peptides bound to HLA-DRB1*1402. The P4 pocket of HLA-DRB1*1402 bound to (f) 
vimentin59-71, (g) vimentin-64Cit59-71 and (h) fibrinogen β 74Cit69-81. The P4-Arg in the 
vimentin59-71 peptide is buried in the P4 pocket, The P4-Cit of the vimentin-64Cit59-71 and 
fibrinogen β 74Cit69-81 peptide adopts an upright conformation  
  
Figure 4. Presentation of vimentin59-71 and vimentin-64Cit59-71 self-antigens in context of 
HLA-DRB1*14:02 to CD4+ T cells in individuals with and at high risk of ACPA+ RA. 
(a-d) PBMC from HLA-DRB1*14:02+ RA patients W1:1-10 and HLA-DRB1*14:02+ FDR 
W1:1-10 were stained with PE-labelled HLA-DRB1*1402-vimentin64Cit59-71 or HLA-
DRB1*14:02-vimentin59-71 tetramer, CD4-APC, CD25-PE/Cy7, and CD127-BV421. Live 
CD4+ FITC-lineage-negative tetramer+ T cells were gated based on an FMO sample stained 
with unlabelled primary and conjugated secondary antibodies. The number calculated relative 
to the CD4+ T cell count, (a) and mean fluorescence intensity (MFI) (b) of tetramer+ cells 
within the total CD4+ population is shown for RA patients and FDR; (c) the proportion of 
CD4+CD25+CD127+ Teff and CD4+CD25+CD127- Treg within vimentin64Cit59-71-reactive 
and vimentin59-71-reactive CD4+ T cell gates and the total CD4+ gate is shown for pooled RA 
patients and FDR. (d) The numbers of vimentin64Cit59-71-reactive and vimentin59-71-reactive 
CD4+ T cells were correlated in pooled RA patients and FDR (R2 0.74, p<0.0001). (e) The 
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Teff/Treg ratio of vimentin64Cit59-71 and vimentin59-71-reactive CD4+ T cells is plotted relative 
to total CD4+ T cell ratio in pooled RA patients and FDR; (f) CD45RO+CD28+, (g) 
CD45RO+CD69+ and CD45RO+CD69+ NKG2D+ vimentin59-71-reactive CD4+, 
vimentin64Cit59-71-reactive CD4+ and total CD4+ T cells are plotted in pooled RA patients 
W2:1-3 and FDR W2:1-3. (h) Frequencies of V-J pairing for TCRα and TCRβ among 
vimentin64Cit59-71-specific and vimentin59-71-specific CD4+ T cells from HLA-DRB1*14:02+ 
RA patients (n=5) and FDR (n=5), and tetramer-negative CD3+ T cells sorted from 
DRB1*14:02+ RA patients (n=3). The width of the bands is proportional to the frequency of 
TCR sequences with a particular V-J pairing. Details of productive TCRα and TCRβ 
sequences in Supplementary Table 4 and Table 2. The figures were generated using the Circos 
online Table Viewer software (http://mkweb.bcgsc.ca/tableviewer/). (i) 106 P2F3 SKW3 cells 
were stimulated with 5 ng/mL unlabelled HLA-DRB1*14:02-vimentin59-71 or HLA-
DRB1*14:02-vimentin-64Cit59-71 tetramer for 4 hours at 37C. Cells were fixed and 
permeabilised, then stained with PerCP/ Cy5.5-ERK1/2 and PB-CD3. Live CD3+ cells 
expressing the GFP marker gene were gated. Need to indicate how many times this experiment 
was done. 
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Tables 
Table 1. Association of HLA-DRB1*14:02 with all RA and seropositive RA in INA RA 
patients and controls.  
Patients and controls were stratified according to the presence of SE. SE-positive individuals 
were further stratified as shown. Other SE-alleles included DRB1*01:01, *01:02, *04:01, 
*04:04, *04:05, *04:08, *04:10, *04:13, and *10:01. HC: healthy controls. 
 
 
HC 
n (%) 
All RA 
n (%) 
OR 
(CI) 
P Seropositive  
RA, n (%) 
OR 
(CI) 
P 
SE- 106 (30) 51 (15) REF  32 (15) REF  
14:02+/ 
other SE- 
64 (18) 80 (23) 2.60 
(1.63-4.15) 
0.0001 46 (21) 2.38 
(1.38-4.12) 
0.0019 
14:02-/ 
other SE+ 
147 (42) 178 (52) 2.52 
(1.69-3.75) 
<0.0001 117 (54) 2.64 
(1.66-4.19) 
<0.0001 
14:02+/ 
other SE+ 
35 (10) 35 (10) 2.08 
(1.17-3.70) 
0.0127 23 (11) 2.18 
(1.13-4.20) 
0.02 
Any SE+ 246 (70) 293 (85) 
2.48 
(1.70-3.60) 
<0.0001 186 (85) 
2.46 
(1.58-3.81) 
0.0001 
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Table 2. Repeated TCR TRAV, TRBV and TRAV/TRBV clonotypes used by HLA-
DRB1*14:02-restricted vimentin59-71 or vimentin64Cit59-71-reactive CD4+ T cells.  
TCR repertoire analysis was undertaken in RA patients W1:1-5 and FDR W1:1-5. Productive 
single TRAV and TRBV clonotypes detected from 2 RA patients and 3 FDR are shown. 
Frequency reflects the frequency of the repeated TRAV or TRBV clonotype divided by the 
total number of tetramer+ cells with productive TRAV or TRBV sequence, for each individual. 
*^ nucleotide sequences encoding each of the public CDR3 amino acid sequences, which 
require a minimal number of N or P additions to be produced. Nucleotides attributed by the 
germline V, D and J genes are shown in blue, red and green respectively. N-additions are 
in black and P-additions in purple text. The nucleotides at the D-J junction encoding the same 
amino acid are underlined in each case. 
Subject  Tetramer TRAV CDR3 TRAJ Frequency 
no./total,  (%) 
HLA-DRB1 
RA W1:1 Cit-vimentin 13-2 SQPGTAL 15 2/17 (11.8%) 14:02, 14:02 
RA W1:2  Vimentin 26-1 SGAGSYQL 28 5/13 (38%) 04:04, 14:02 
Subject  Tetramer TRBV CDR3 TRBJ Frequency* (%)  
RA W1:1 Cit-vimentin 2 SEAADNEQ 2-1 2/14 (14.2%) 14:02, 14:02 
RA W1:2 Vimentin 10-3 GGTRTESSYEQ 2-7 2/5 (40%) 04:04, 14:02 
*FDR W1:3  Cit-vimentin 30 SIGAGNQPQ 1-5 1/19 (5.2%) 
04:04, 14:02 
*FDR W1:3 Vimentin 30 SIGAGNQPQ 1-5 3/7 (42.8%) 
^FDR W1:5 Cit-vimentin 30 SVGAGNQPQ 1-5 2/2 (100%) 
13:02, 14:02 
^FDR W1:5 Vimentin 30 SVGAGNQPQ 1-5 2/6 (33%) 
Subject  Tetramer TRAV/ 
TRBV 
CDR3a/CDR3 TRAJ/
TRBJ 
Frequency* (%)  
RA W1:1 Cit-vimentin 13-2/2 SQPGTAL/ 
SEAADNEQ 
15/ 
2-1 
2/12 (16.6%) 14:02, 14:02 
 
  
 24 
Subject TRBV 
*FDR W1:3 30*01 S I G A G N Q P Q  
agt atc ggg gcg ggc aat cag ccc cag  
^FDR W1:5 30*01 S V G A G N Q P Q  
agt gtg ggg gca ggc aat cag ccc cag  
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